National, 8th December: The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert, urging healthcare professionals and patients to remain vigilant regarding adverse reactions linked to the painkiller Meftal, as per media reports.
Meftal, commonly prescribed for menstrual cramps and rheumatoid arthritis, contains mefenamic acid and is used for conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhea, mild to moderate pain, inflammation, fever, and dental pain.
This cautionary measure comes after a preliminary analysis of adverse drug reactions reported in the Pharmacovigilance Programme of India (PvPI) database. The analysis identified instances of drug reactions leading to eosinophilia and systemic symptoms (DRESS) syndrome.
Healthcare professionals and consumers have been advised to closely monitor the potential for the mentioned adverse drug reaction (ADR) associated with Meftal’s use. If such reactions occur, the alert recommends reporting the matter to the national coordination centre of the PvPI under the IPC.
The Indian Pharmacopoeia Commission, an autonomous institution of the Ministry of Health and Family Welfare, establishes standards for all drugs manufactured, sold, and consumed in India.
Read More: Tripura Government Extends Jobs to 15 Families Affected by Political Violence